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The effects of sequential treatment as a first-line therapy
for Helicobacter pylori eradication
Mehmet DEMİR, Hilmi ATASEVEN

Aim: There is no effective eradication regimen for Helicobacter pylori (HP) in Turkey. Recent studies have shown that
sequential therapy may be superior to the standard triple therapy in terms of the eradication of HP. In this study, we aim
to assess the efficacy of a 14-day sequential treatment regimen as a first-line therapy for HP eradication.
Materials and methods: This is a prospective, open-label, single-centre study. The study involved 86 consecutive
patients with nonulcer dyspepsia. All patients were randomly assigned into 2 study groups at a 2:1 ratio using random
sampling numbers. The first group of patients were administered a sequential treatment: pantoprazole 2 × 40 mg and
amoxicillin 2 × 1000 mg for the first 7 days and pantoprazole 2 × 40 mg, metronidazole 2 × 500 mg, and tetracycline 4 ×
500 mg for the remaining 7 days. The second group of patients were administered pantoprazole 2 × 40 mg, amoxicillin
2 × 1000 mg, and clarithromycin 2 × 500 mg (PAC) for 14 days. Eradication was defined as the absence HP as assessed
with the (14-C) urea breath test 4 weeks after the end of the antimicrobial therapy.
Results: The eradication rate in the sequential group was 56.1% for the ITT analysis and 57.1% for the PP analysis, the
eradication rate of the PAC group was 58.6 % for both PP and ITT analysis. There was a statistically significant difference
between the eradication rates of the groups for both PP and ITT analysis. There was no statistically significant difference
in the adverse effects encountered in both groups (10.5% versus 13.8% P > 0.05).
Conclusion: These results suggest that a 14-day sequential eradication regimen is not effective as a first-line therapy for
HP eradication.
Key words: Sequential treatment; helicobacter pylori eradication

Helicobacter pylori eradikasyonu için birinci basamak tedavi
olarak ardışık tedavi rejiminin etkinliği
Amaç: Ülkemizde Helicobacter pylori (HP) için etkili eradikasyon rejimi yoktur. Son dönemlerdeki bilgiler HP
eradikasyonu için ardışık tedavi rejimininin standart üçlü tedaviden üstün olduğunu göstermiştir. Bizim bu çalışmadaki
amacımız HP eradikasyonu için birinci basamak tedavi olarak 14 günlük ardışık tedavi rejiminin etkinliğini araştırmaktı.
Yöntem ve gereç: Bu çalışma prospektif, open-label, tek merkezli bir çalışmadır. Çalışmaya ardışık 86 nonülser dispepsili
hasta dahil edildi. Tüm hastalar rastgele 2 çalışma grubuna 2:1 oranında rastgele örnekleme sayıları kullanarak ayrıldı.
İlk gruptaki hastalara ardışık tedavi verildi; pantoprazol 2 × 40 mg ve amoksisiklin 2 × 1000 mg ilk 7 gün, ve pantoprazol
2 × 40 mg, metronidazol 2 × 500 mg, tetrasiklin 4 × 500 mg geriye kalan 7 gün. İkinci gruptaki hastalara pantoprazol 2
× 40 mg ve amoksisiklin 2 × 1000 mg ve klaritromisin 2 × 500 mg (PAC) verildi.
Bulgular: Ardışık gurupta eradikasyon oranı ITT analizi ile % 56,1 ve PP analizi ile %,57,1, PAC grupta hem ITT hem
de PP analizi ile % 58,6 idi, ve gruplar arasında hem ITT hem de PP analizi ile istatistiksel olarak anlamlı fark yoktu.
Gruplar arasında yan etki açısından istatistiksel olarak anlamlı fark yoktu (% 10,5 karşın % 13,8 P > 0,05).
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Sonuç: Bu sonuçlar HP eradikasyonu için birinci basamak tedavi olarak 14 günlük ardışık tedavi rejiminin etkin
olmadığını düşündürmektedir.
Anahtar sözcükler: Ardışık tedavi, Helicobacter pylori eradikasyonu

Introduction
Helicobacter pylori (HP) is a major cause of illness
and death worldwide. HP plays an important role
in the pathogenesis of chronic gastritis, peptic ulcer
disease, gastric mucosa-associated lymphoid tissue
lymphoma, and gastric adenocarcinoma (1). The
eradication of HP is associated with a decrease in
the recurrence of peptic ulcer and its complications
and regression of low-grade gastric lymphoma in
most cases (2,3). According to Maastricht Consensus
reports issued in 2007, the preferred treatment
regimens were triple treatments including a protonpump inhibitor (PPI) or ranitidine bismuth citrate
(RBC) plus 2 antibiotics (amoxicillin, metronidazole,
or clarithromycin) (4). In Turkey, however, these
treatment regimens only provide eradication in
approximately 50% of the cases of HP infection (58). There is no effective eradication regimen for
HP in our country. Therefore, further therapeutic
approaches are sought for HP infection. Recent data
indicated that sequential therapy may be superior
to standard triple therapy for eradication (9-11).
Unfortunately, there are limited available data about
sequential therapy as a first-line therapy for HP
eradication in Turkey and the data that are available
are often contradictory (12,13). In the present study,
we aimed to assess the efficacy of a 14-day sequential
treatment regimen (pantoprazole 2 × 40 mg and
amoxicillin 2 × 1000 mg for the first 7 days followed
by pantoprazole 2 × 40 mg, tetracycline 4 × 500 mg,
and metronidazole 2 × 500 mg for the remaining 7
days) as a first-line therapy for HP eradication.

including proton pump inhibitors, H-2 receptor
blockers, bismuth preparations, prokinetics, nonsteroidal anti-inflammatory drugs (NSAIDs),
or antibiotics in the preceding 2 months;
alcohol addiction; history of gastric surgery or
cholecystectomy; decompensated congestive heart
failure; liver cirrhosis; chronic renal failure requiring
dialysis; diagnosis of malignancy; pregnancy; and
active infection requiring antibiotherapy.
Diagnosis of HP infection
All patients included in this study underwent
upper gastrointestinal endoscopy (Fujinon EG
450WR5, Japan). In each patient, 2 biopsy specimens
from the antrum and 2 from the corpus were
taken for pathological examinations, and 1 biopsy
specimen was taken from the antrum for a urease
test. The presence of HP was identified by its curvedshape morphology, location on the epithelial cell
surface (within the gastric pits or in the overlying
mucus layer), and positive staining by Giemsa
stain. HP status was evaluated by a rapid urease test
(RUT) and histology by Giemsa stain. Patients with
positive HP results on both histopathology and RUT
were included in the study. Of the 153 patients, 86
patients were found to be HP-positive by both RUT
and histological examination. Of the remaining
67 patients, 1 patient was found to be HP-positive
histologically and negative by RUT, 4 patients were
declared positive by RUT and negative by histologic
examination, and 62 patients were determined to be
negative by both RUT and histologic examination
and were thus excluded from the study.
Treatment regimen

Materials and methods
This was a prospective, randomized, single-centre
study. The study involved 86 consecutive patients
with nonulcer dyspepsia admitted to the Regional
Education and Research Hospital in Erzurum,
Turkey, between September 2008 and May 2009.
Exclusion criteria for all study subjects included
prior HP eradication therapy; use of medication
428

All patients were randomly assigned into
1 of the 2 groups at a 2:1 ratio using random
sampling numbers. The first group of patients was
administered a sequential treatment: pantoprazole 2
× 40 mg and amoxicillin 2 × 1000 mg for the first
7 days and pantoprazole 2 × 40 mg, metronidazole
2 × 500 mg, and tetracycline 4 × 500 mg for the
remaining 7 days. The second group of patients was
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administered pantoprazole 2 × 40 mg, amoxicillin 2
× 1000 mg, and clarithromycin 2 × 500 mg (PAC) for
14 days. Eradication was defined as the absence HP
as assessed with the (14-C) urea breath test 4 weeks
after the end of the antimicrobial therapy.
Compliance and safety
Compliance and the frequency of side effects were
assessed using a diary completed by the patient during
treatment. At the end of the first week and the second
week, side-effects of the treatment were evaluated.
All adverse events were recorded, irrespective of the
relationship to the study medication as assessed by
the physician. Compliance with therapy was assessed
through return pill count for each patient.
Ethics and consent
The study protocol was carried out in accordance
with the Helsinki Declaration revised in 1989, and
each patient provided written informed consent in
accordance with the Helsinki Declaration.
Statistical analyses
Data were analyzed using SPSS software (Statistical
Package for the Social Sciences, version 13.0, SPSS
Inc, Chicago, IL, USA). Results are expressed as
means ± standard deviation. Statistically significant
differences between groups were assessed using the t or
chi-square tests. P values below 0.05 were considered
statistically significant in all analyses. We calculated
the per-protocol (PP) and intention-to-treat (ITT)
eradication rates and 95% confidence intervals (CI)
for both treatments. For the PP analysis, only patients
who took all of their medications for the prescribed
duration of the therapy were evaluated. For the ITT
analysis, all patients were included, including those
non-compliant and those who did not complete the
full course of therapy.
Results

in the sequential group and 48.2% (14/29) in the PAC
group. There was no significant difference between
the current smoking of the 2 groups (P > 0.05).
The baseline characteristics according of groups are
presented in Table 1.
Patient compliance and side-effects
Drug compliance was at an acceptable rate.
Compliance rates among sequential group and
PAC group were 94% and 98%, respectively. In
the sequential group, side-effects were observed
in 6 patients (10.5%). They were abdominal pain
or discomfort in 2 patients (3.5%), diarrhea in 2
patients (3.5%), nausea and/or vomiting in 1 patient
(1.75%), and bloating in 1 patient (1.75%). In the
PAC group, side-effects were observed in 4 patients
(13.8%). They were abdominal pain or discomfort
in 1 patient (3.45%), diarrhea in 1 patient (3.45%),
constipation in 1 patient (3.45%), and headache in 1
patient (3.45%). There was no statistically significant
difference between the incidence of side effects
among the 2 groups (P = 0.655). One patient in the
sequential group could not complete the treatment
due to severe nausea and vomiting; 56 out of 57
patients completed the study. None of the patients
in the PAC group discontinued treatment because of
side-effects and all patients were able to complete the
study. The distribution of adverse effects among the
groups is presented in Table 2.
Eradication of HP
The eradication rate in the sequential group
was 56.1% (32/57) for the ITT analysis and 57.1%
(32/56) for the PP analysis; the eradication rate of
PAC group was 58.6% for both ITT and PP analysis.
The eradication rates were not significantly different
between the groups with both ITT and PP analysis.
All eradication rates, treatment differences, and
95% confidence limits of the eradication rates and
differences are summarized in Table 3.

Demographic data
After exclusions, the study population consisted
of 57 patients in the sequential group (29 females, 28
males; mean age: 39.1 ± 14.5 years) and 29 patients
in the PAC group (15 females, 14 males; mean age:
38.9 ± 12.9 years). There was no significant difference
between the gender and mean age of the 2 groups (P
> 0.05). The current smoking ratio was 49.1% (28/57)

Discussion
The European Helicobacter pylori Study Group
guidelines advocate a proton pump inhibitor plus
2 antibiotics (clarithromycin or metronidazole in
combination with amoxicillin) as a first-line therapy
for HP eradication. However, an epidemiologic
analysis of trends over 10 years (1996-2005) in the
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Table 1. Demographic and clinical characteristics of the patients.
Sequential group

PAC group

P value

n

57

29

Age

39.1 ± 14.5

38.9 ± 12.9

NS

Sex (Male/Female)

28/29

14/15

NS

Current smoking (n) (%)

28 (49.1%)

14 (48.2%)

NS

N: number of patients; NS: nonsignificant; F: females, M: males; PAC: pantoprazole - amoxicillin - clarithromycin

Table 2. Distribution of adverse effects among the sequential group and the PAC group.

Sequential group

PAC group

n: 57

n: 29

Abdominal pain or discomfort

2 (3.5%)

1 (3.45%)

Diarrhea

2 (3.5%)

1 (3.45%)

Nausea and/or vomiting

1 (1.75%)

-

Constipation

-

1 (3.45%)

Bloating

1 (1.75%)

-

Headache

-

1 (3.45%)

Total (n) (%)

6 (10.5%)

4 (13.8%)

P value
Adverse events (n) (%)

NS

N: number of patients; NS: nonsignificant; PAC: pantoprazole - amoxicillin - clarithromycin

Table 3. Rates of Helicobacter pylori eradication in 2 different treatment regimens

Sequential group

PAC group

P value

ITT
% (95% CI)

32/57
56.1% (43%-68%)

17/29
58.6% (40%-76%)

>0.05

PP
% (95% CI )

32/56
57.1% (44%-70%)

17/29
58.6% (40%-76%)

>0.05

n: total number of patients, CI: confidence intervals, PP: per protocol, ITT: Intention-to- treat, PAC: pantoprazole-amoxicillinclarithromycin
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Turkish population reported a gradual of decrease
in the of eradication success from 79.4% to 61.1% by
administering a PPI, amoxicillin, and clarithromycin
combination (4,5). In our study, the eradication rate
of HP in the PAC group was 58.6%, which was in
accordance with the aforementioned study. Recent
data suggest that clarithromycin resistance is a
growing problem affecting the eradication rate of the
HP. It has been shown in a meta-analysis that the cure
rate of the infection is reduced to 55% in patients with
clarithromycin resistance (14). The rate of resistance
to clarithromycin has increased gradually in Turkey.
Recently, a study on Turkish dyspeptic population
revealed a clarithromycin resistance of 40.2% using
PCR method (15). Analysis of the abstracts of the
Turkish Gastroenterology Congress from 2001 to
2006 revealed a significant increase in clarithromycin
resistance that paralleled the increase in eradication
failure (5). Accordingly, we theorized that the cause
of the low eradication rate in the PAC group may be
related to the higher prevalence of clarithromycin
resistance in this country.
Recent interest has focused on sequential therapy,
which consists of 5 or 7 days of treatment with a
proton-pump inhibitor and one antibiotic (usually
amoxicillin) followed by 5 or 7 days of treatment with
the proton-pump inhibitor and 2 other antibiotics
(usually clarithromycin and a 5-nitroimidazole)
(10-13). The rationale for this more complicated
approach is that amoxicillin may weaken bacterial
cell walls in the initial phase of treatment, preventing
the development of drug efflux channels that inhibit
such drugs as clarithromycin from binding to
ribosomes. This may help to improve the efficacy of
clarithromycin in the second phase of treatment (16).
Recent data showed that the sequential treatment
regimen achieved a significantly higher eradication
rate of HP when compared to the standard PPIbased triple regimen in this small selected population
(11,12). In this study, HP eradication rates in the
sequential therapy group were 56.1% and 57.1% with
ITT and PP analyses, respectively, and the overall
eradication rate was not significantly better than
that of the triple eradication regimen (58.6% with
both ITT and PP analysis) (P > 0.05). The results of
previous studies in Turkey are controversial. Uygun

et al. reported that a 14-day sequential treatment
regimen was significantly more effective than 14
days of triple treatment (72.6% versus 58% with ITT
analysis, 80.1% versus 63% with PP analysis) (12).
However, Sezgin et al. reported that eradication
rates with a 14-day sequential treatment regimen
(pantoprazole 40 mg b.d. plus amoxicillin 1000
mg b.d. for 7 days and pantoprazole 40 mg b.d.,
metronidazole 500 mg b.d., and tetracycline 500
mg q.d. for the remaining 7 days) were 50% for the
ITT analysis and 57% for the PP analysis (13). Our
findings were in accordance with those of Sezgin et
al. (50% versus 56.1% for the ITT analysis and 57%
versus 56.1% for the PP analysis). Therefore, our
findings suggest that sequential treatment regimens
do not have better eradication rates than standard
triple therapies in the first-line eradication of HP.
The sequential eradication regimen is not effective
as a first-line therapy for HP eradication and it is not
clear why. The cause of the low eradication rate in
the PAC group may be related to higher prevalence
of clarithromycin resistance in this country, but, in
our study, the sequential eradication regimen did not
include clarithromycin. Studies performed in Turkey
have also shown a high prevalence of metronidazole
resistance (50%-60%) (17,18). This factor could be
responsible for the ineffective eradication, but in vitro
resistance to metronidazole is not always predictive
of in vivo resistance (19,20). However, increasing
the dosage of metronidazole to 500 mg improves the
results of therapy when the doses are administered 3
times per day (21).
Drug compliance in the sequential group was at an
acceptable rate. In the previous studies, the prevalence
of the reported adverse effects with a sequential
regimen was low (7%, 36 of 522 patients), and all of
the adverse effects were minor (9). The prevalence of
them with a 14-day sequential eradication regimen
was nearly 10% and no statistically significant
differences were found between the triple eradication
regimen and the sequential eradication regimen (12).
In the present study, adverse effects were detected in
10.2% of patients in the sequential group and 13.8%
in the PAC group, although the difference between
groups did not reach statistical significance (P > 0.05).
These observations suggest that a 14-day sequential
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The lack of any specific susceptibility testing
for antibiotics, the non double-blind nature of the
study, and the relatively small number of subjects
were the most important limitations of the present
study. However, antibiotic susceptibility tests are
not routinely performed in the first-line eradication
treatment of HP and, therefore, the clinical validity of
the study is not affected.

rate in both patients with diabetes mellitus and nondiabetic patients, 81% and 85%, respectively (22).
Higher eradication rate is likely to be achieved by
quadruple therapy because of the high prevalence
of clarithromycin resistance in our populations.
In regions that demonstrate a high prevalence of
antibiotic resistance (>15%-20%), quadruple therapy
is widely recommended (4). The bismuth-based
quadruple therapy can therefore be proposed as a
first-line therapy for HP eradication in Turkey.

There is no effective treatment that can be
offered as a first-line therapy for HP eradication in
this country. We recently showed that the bismuthbased quadruple eradication regimen as first-line
therapy is safe, tolerable, and achieves a high cure

In conclusion, these results suggest that a 14-day
sequential eradication regimen is not effective as a
first-line therapy for HP eradication. Further studies
with new antibiotic associations are needed for more
effective eradication of HP in Turkey.

eradication regimen is tolerable and compliance is
good.

References
1.

Dunn BE, Cohen H, Blaser MJ. Helicobacter pylori. Clinical
Microbiology Reviews 1997; 10: 720-741.

2.

Wong BCY, Lam SK, Lai KC, Hu WH, Ching CK, Ho J et al.
Triple therapy for Helicobacter pylori eradication is more
effective than long-term maintenance antisecretory treatment
in the prevention of recurrence of duodenal ulcer: a prospective
long-term follow-up study. Aliment Pharmacol Ther 1999; 13:
303-309.

3.

Bayerdörffer E, Neubauer A, Rudolph B, Thiede C, Lehn N, Eidt
S et al. Regression of primary gastric lymphoma of mucosaassociated lymphoid tissue type after cure of Helicobacter pylori
infection. MALT Lymphoma Study Group. Lancet 1995; 345:
1591-1594.

4.

Malfertheiner P, Megraud F, O’Morain C, Bazzoli F, El-Omar
E, Graham D et al. Current concepts in the management of
Helicobacter pylori infection – The Maastricht III consensus
report. Gut 2007; 56: 772-81.

5.

Kadayıfcı A, Buyukhatipoglu H, Savas M Cemil, Simsek I.
Eradication of Helicobacter pylori with triple therapy: An
epidemiologic analysis of trends in Turkey over 10 years. Clin
Ther 2006; 11: 1960-1966.

6.

Uygun A, Kadayıfçı A, Yeşilova Z. Hp eradikasyonunda
lansoprazol ve pantoprazol içeren üçlü rejimlerin etkinliginin
karşılaştırılması (Comparison of effectiveness of lansoprazole
and pantoprazole based triple therapy in Helicobacter pylori
eradication). Turk J Gastroenterol 2003; (Suppl): PB.08/33)

7.

432

Güliter S, Keleş H, Özkurt ZN, Cengiz DU, Kolukısa E. Can
lansoprazole, amoxicillin and clarithromycin combination still
be used as a first-line therapy for eradication of Helicobacter
pylori? Turk J Gastroenterol 2005; 16: 29-33.

8.

Ertaş E, Tüzün A, Özden A. Helicobacter pylori pozitif fonksiyonel
dispepside 7 ve 14 günlük pantoprazol, klaritromisin,
amoksisilin kombinasyon tedavisinin eradikasyon etkinliginin
ve eradikasyonun dispeptik semptomlar üzerine etkilerinin
degerlendirilmesi. (Effectiveness of 7 and 14 days pantoprazole,
amoxicillin, clarithromycin combination treatments in
Helicobacter pylori positive functional dyspepsia). Turk J
Gastroenterol 2004; (Suppl): PB.08/18.

9.

Zullo A, Vaira D, Vakil N, Hassan C, Gatta L, Ricci C et al. High
eradication rates of Helicobacter pylori with a new sequential
treatment. Aliment Pharmacol Ther 2003; 17: 719-26.

10.

Jafri NS, Hornung CA, Howden CW. Meta-analysis: sequential
therapy appears superior to standard therapy for Helicobacter
pylori infection in patients naive to treatment. Ann Intern Med
2008; 17: 148: 923-31.

11.

Tong JL, Ran ZH, Shen J, Xiao SD. Sequential therapy vs.
standard triple therapies for Helicobacter pylori infection: a
meta-analysis. J Clin Pharm Ther 2009; 34: 41-53.

12.

Uygun A, Kadayifci A, Yesilova Z, Safali M, Ilgan S, Karaeren
N. Comparison of sequential and standard triple-drug regimen
for Helicobacter pylori eradication: a 14-day, open-label,
randomized, prospective, parallel-arm study in adult patients
with nonulcer dyspepsia. Clin Ther 2008; 30: 528-34.

13.

Sezgin O, Altintaş E, Nayir E, Uçbilek E. A pilot study evaluating
sequential administration of a PPI-amoxicillin followed by a
PPI-metronidazole-tetracycline in Turkey. Helicobacter. 2007;
12: 629-32.

14.

Dore MP, Leandro G, Realdi G, Sepulveda AR, Graham DY.
Effect of pretreatment antibiotic resistance to metronidazole
and clarithromycin on outcome of Helicobacter pylori therapy:
a meta-analytical approach. Dig Dis Sci 2000; 45: 68-76.

M. DEMİR, H. ATASEVEN

15.

Sezgin O, Aslan G, Altintaş E, Tezcan S, Serin MS, Emekdaş
G. Detection of point mutations on 23S rRNA of Helicobacter
pylori and resistance to clarithromycin with PCR-RFLP
in gastric biopsy specimens in Mersin, Turkey. Turk J
Gastroenterol 2008; 19: 163-7.

16.

De Francesco V, Margiotta M, Zullo A, Hassan C, Troiani L,
Burattini O et al. Clarithromycin-resistant genotypes and
eradication of Helicobacter pylori. Ann Intern Med. 2006; 144:
94-100.

17.

Agel E, Durmaz B, Tevfik MR, Asgın R. The isolation rate and
antibiotic resistant pattern of Helicobacter pylori in dyspeptic
patients. Turk J Med Sci 2000; 30: 143-146.

18.

Goral V, Fadile YZ, Gül K. Helikobakter pilori infeksiyonunda
antibiyotik direnci. T. Klin Gastroenterohepatol 2000; 11: 8792.

19.

Graham DY. Antibiotic resistance in Helicobacter pylori:
implications for therapy. Gastroenterology 1998; 115: 12721277.

20.

Debets-Ossenkopp YJ, Herscheid AJ, Pot RG, Kuipers
EJ, Kusters JG, Vandenbroucke-Grauls CM. Prevalence
of Helicobacter pylori resistance to metronidazole,
clarithromycin, amoxicillin, tetracycline and trovafloxacin in
The Netherlands. J Antimicrob Chemother 1999; 43: 511-515.

21.

de Boer WA. How to achieve a near 100% cure rate for H. pylori
infection in peptic ulcer patients: a personal viewpoint. J Clin
Gastroenterol 1996; 22: 313-316.

22.

Demir M, Göktürk S, Oztürk NA, Serin E, Yilmaz U. Bismuthbased first-line therapy for Helicobacter pylori eradication in
type 2 diabetes mellitus patients. Digestion 2010; 82: 47-53.

433

